These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 29146380)
1. Inclusion of the value of herd immunity in economic evaluations of vaccines. A systematic review of methods used. Nymark LS; Sharma T; Miller A; Enemark U; Griffiths UK Vaccine; 2017 Dec; 35(49 Pt B):6828-6841. PubMed ID: 29146380 [TBL] [Abstract][Full Text] [Related]
2. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine. Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273 [TBL] [Abstract][Full Text] [Related]
3. Dynamic transmission models and economic evaluations of pneumococcal conjugate vaccines: a quality appraisal and limitations. Løchen A; Anderson RM Clin Microbiol Infect; 2020 Jan; 26(1):60-70. PubMed ID: 31055164 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects. Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089 [TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of pediatric influenza immunization program compared with other pediatric immunization programs: A systematic review. Gibson E; Begum N; Sigmundsson B; Sackeyfio A; Hackett J; Rajaram S Hum Vaccin Immunother; 2016 May; 12(5):1202-16. PubMed ID: 26837602 [TBL] [Abstract][Full Text] [Related]
7. Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review. Saokaew S; Rayanakorn A; Wu DB; Chaiyakunapruk N Pharmacoeconomics; 2016 Dec; 34(12):1211-1225. PubMed ID: 27510721 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines. Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516 [TBL] [Abstract][Full Text] [Related]
9. [Vaccination--value for money?]. Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Kristiansen IS Tidsskr Nor Laegeforen; 2006 Oct; 126(20):2670-3. PubMed ID: 17057767 [TBL] [Abstract][Full Text] [Related]
10. Systematic review of economic evaluation analyses of available vaccines in Spain from 1990 to 2012. Cortés I; Pérez-Camarero S; Del Llano J; Peña LM; Hidalgo-Vega A Vaccine; 2013 Aug; 31(35):3473-84. PubMed ID: 23764534 [TBL] [Abstract][Full Text] [Related]
11. Systematic review of incremental non-vaccine cost estimates used in cost-effectiveness analysis on the introduction of rotavirus and pneumococcal vaccines. De la Hoz-Restrepo F; Castañeda-Orjuela C; Paternina A; Alvis-Guzman N Vaccine; 2013 Jul; 31 Suppl 3():C80-7. PubMed ID: 23777697 [TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland. Tilson L; Usher C; Butler K; Fitzsimons J; O'Hare F; Cotter S; O'Flanagan D; Johnson H; Barry M Value Health; 2008; 11(5):898-903. PubMed ID: 18489504 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Melegaro A; Edmunds WJ Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches. Kim SY; Goldie SJ Pharmacoeconomics; 2008; 26(3):191-215. PubMed ID: 18282015 [TBL] [Abstract][Full Text] [Related]
15. Cost Effectiveness of HPV Vaccination: A Systematic Review of Modelling Approaches. Pink J; Parker B; Petrou S Pharmacoeconomics; 2016 Sep; 34(9):847-61. PubMed ID: 27178048 [TBL] [Abstract][Full Text] [Related]
16. Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands. Hubben GA; Bos JM; Glynn DM; van der Ende A; van Alphen L; Postma MJ Vaccine; 2007 May; 25(18):3669-78. PubMed ID: 17360082 [TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales. Atkins KE; Shim E; Carroll S; Quilici S; Galvani AP Vaccine; 2012 Nov; 30(48):6766-76. PubMed ID: 23000223 [TBL] [Abstract][Full Text] [Related]
18. Surveillance of the impact of pneumococcal conjugate vaccines in developing countries. Rodgers GL; Klugman KP Hum Vaccin Immunother; 2016; 12(2):417-20. PubMed ID: 26309055 [TBL] [Abstract][Full Text] [Related]
19. The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity. Armstrong GL; Billah K; Rein DB; Hicks KA; Wirth KE; Bell BP Pediatrics; 2007 Jan; 119(1):e22-9. PubMed ID: 17200247 [TBL] [Abstract][Full Text] [Related]
20. Systematic review of rotavirus vaccination cost-effectiveness in high income settings utilising dynamic transmission modelling techniques. Jesudason T; Rodarte A; Tordrup D; Carias C; Chen YH Vaccine; 2023 Aug; 41(36):5221-5232. PubMed ID: 37479614 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]